Literature DB >> 21556437

Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals.

Meghan A Campbell1, Jesper Wengel.   

Abstract

Oligonucleotide chemistry has been developed greatly over the past three decades, with many advances in increasing nuclease resistance, enhancing duplex stability and assisting with cellular uptake. Locked nucleic acid (LNA) is a structurally rigid modification that increases the binding affinity of a modified-oligonucleotide. In contrast, unlocked nucleic acid (UNA) is a highly flexible modification, which can be used to modulate duplex characteristics. In this tutorial review, we will compare the synthetic routes to both of these modifications, contrast the structural features, examine the hybridization properties of LNA and UNA modified duplexes, and discuss how they have been applied within biotechnology and drug research. LNA has found widespread use in antisense oligonucleotide technology, where it can stabilize interactions with target RNA and protect from cellular nucleases. The newly emerging field of siRNAs has made use of LNA and, recently, also UNA. These modifications are able to increase double-stranded RNA stability in serum and decrease off-target effects seen with conventional siRNAs. LNA and UNA are also emerging as versatile modifications for aptamers. Their application to known aptamer structures has opened up the possibility of future selection of LNA-modified aptamers. Each of these oligonucleotide technologies has the potential to become a new type of therapy to treat a wide variety of diseases, and LNA and UNA will no doubt play a part in future developments of therapeutic and diagnostic oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21556437     DOI: 10.1039/c1cs15048k

Source DB:  PubMed          Journal:  Chem Soc Rev        ISSN: 0306-0012            Impact factor:   54.564


  46 in total

Review 1.  Beyond DNA origami: the unfolding prospects of nucleic acid nanotechnology.

Authors:  Nicole Michelotti; Alexander Johnson-Buck; Anthony J Manzo; Nils G Walter
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-11-30

2.  Conformational constraints of cyclopentane peptide nucleic acids facilitate tunable binding to DNA.

Authors:  Hongchao Zheng; Istvan Botos; Victor Clausse; Herman Nikolayevskiy; Elizabeth E Rastede; Munira F Fouz; Sharlyn J Mazur; Daniel H Appella
Journal:  Nucleic Acids Res       Date:  2021-01-25       Impact factor: 16.971

3.  Quick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cells.

Authors:  Nihal G Maremanda; Kislay Roy; Rupinder K Kanwar; Vidyarani Shyamsundar; Vijayalakshmi Ramshankar; Arvind Krishnamurthy; Subramanian Krishnakumar; Jagat R Kanwar
Journal:  Biomicrofluidics       Date:  2015-09-29       Impact factor: 2.800

Review 4.  Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease.

Authors:  Artin Soroosh; Marina Koutsioumpa; Charalabos Pothoulakis; Dimitrios Iliopoulos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-11-16       Impact factor: 4.052

Review 5.  Anti-miRNA oligonucleotides: A comprehensive guide for design.

Authors:  Joana Filipa Lima; Laura Cerqueira; Ceu Figueiredo; Carla Oliveira; Nuno Filipe Azevedo
Journal:  RNA Biol       Date:  2018-03-23       Impact factor: 4.652

Review 6.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

Review 7.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

8.  Nucleic Acid Targeted Therapy: G4 Oligonucleotides Downregulate HRAS in Bladder Cancer Cells through a Decoy Mechanism.

Authors:  Giulia Miglietta; Alaa S Gouda; Susanna Cogoi; Erik B Pedersen; Luigi E Xodo
Journal:  ACS Med Chem Lett       Date:  2015-10-18       Impact factor: 4.345

9.  Detection of mRNA in living cells by double-stranded locked nucleic acid probes.

Authors:  Reza Riahi; Zachary Dean; Ting-Hsiang Wu; Michael A Teitell; Pei-Yu Chiou; Donna D Zhang; Pak Kin Wong
Journal:  Analyst       Date:  2013-06-17       Impact factor: 4.616

10.  Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer.

Authors:  Parag Parekh; Sanchit Kamble; Nianxi Zhao; Zihua Zeng; Bryce P Portier; Youli Zu
Journal:  Biomaterials       Date:  2013-08-19       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.